Mary Wilson
Well-known member
Duke Global Health Innovation Center
Updated: December 11, 2020
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Also unprecedented is the number of advance market commitments (AMCs) made by countries and multilateral partnerships eager to reserve vaccine supply, even before any candidates are on the market.
...
Current models predict that there will not be enough vaccines to cover the world's population until 2023or 2024. Manufacturing capacity can be expanded with targeted investment but only to an extent and it will remain a rate limiter.
...
Despite this public commitment to equity, individual countries are incentivized to purchase as many vaccine doses (and from as wide a pool of candidates) as possible in order to increase their chances of covering their population. Before any vaccine candidates are even approved for market, confirmed purchases cover 7.2 billion doses, with another 2.4 billion doses currently under negotiation or reserved as optional expansions of existing deals.
https://launchandscalefaster.org/COVID-19
Updated: December 11, 2020
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Also unprecedented is the number of advance market commitments (AMCs) made by countries and multilateral partnerships eager to reserve vaccine supply, even before any candidates are on the market.
...
Current models predict that there will not be enough vaccines to cover the world's population until 2023or 2024. Manufacturing capacity can be expanded with targeted investment but only to an extent and it will remain a rate limiter.
...
Despite this public commitment to equity, individual countries are incentivized to purchase as many vaccine doses (and from as wide a pool of candidates) as possible in order to increase their chances of covering their population. Before any vaccine candidates are even approved for market, confirmed purchases cover 7.2 billion doses, with another 2.4 billion doses currently under negotiation or reserved as optional expansions of existing deals.
https://launchandscalefaster.org/COVID-19